FindTrial
Sign In

Placebo of LCZ696

DRUG6 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Myocardial InfarctionChronic Heart Failure (CHF)Essential HypertensionHeart Failure and Reduced Ejection FractionHypertensionPediatric Heart Failure

Phase 2

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
CompletedNCT02678312
Novartis PharmaceuticalsPediatric Heart Failure
Start: 2016-11-03End: 2022-01-03Updated: 2023-02-10

Phase 3

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
CompletedNCT01785472
Novartis PharmaceuticalsEssential Hypertension
Start: 2013-04-30End: 2014-08-31Updated: 2016-12-29
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
CompletedNCT01876368
Novartis PharmaceuticalsHypertension
Start: 2013-09-30End: 2014-08-31Updated: 2015-12-07
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
CompletedNCT02884206
Novartis PharmaceuticalsChronic Heart Failure (CHF)
Start: 2016-11-23End: 2022-05-16Updated: 2024-08-06
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
CompletedNCT02924727
Novartis PharmaceuticalsAcute Myocardial Infarction
Start: 2016-12-09End: 2021-02-26Updated: 2023-06-22

Phase 4

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
CompletedNCT02874794
Novartis PharmaceuticalsHeart Failure and Reduced Ejection Fraction
Start: 2016-08-17End: 2019-01-26Updated: 2021-01-05

Related Papers

Changes in cardiac structure and function are associated with health‐related quality of life in heart failure patients with reduced ejection fraction: Results from the <scp>EVALUATE</scp> ‐ <scp>HF</scp> trial
European Journal of Heart Failure2025-07-181 citations
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.
2024-10-016 citations
Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial
Circulation2024-09-2531 citations
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
2024-03-0111 citations
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
Journal of the American Heart Association2023-08-2313 citations
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Circulation Heart Failure2023-05-0142 citations
Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial
Circulation Heart Failure2023-01-0526 citations
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
Circulation2022-11-0227 citations
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy
Circulation2022-10-0356 citations
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: <scp>the EVALUATE‐HF trial</scp>
European Journal of Heart Failure2022-05-1320 citations
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan
JACC Heart Failure2022-01-1223 citations
Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
New England Journal of Medicine2021-11-10274 citations
Do sacubitril/valsartan affect neurocognitive function?
Annual for Hospital Pharmacy2021-10-14
Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study
Circulation Heart Failure2021-03-0112 citations
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
2020-10-1623 citations
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
2020-01-1613 citations
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction
JAMA2019-09-02309 citations